Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

POWDOX 125 mg/g premix for medicated feeding stuff for pigs

CORREO ELECTRÓNICO

mresvet@aemps.es

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/223/001/DC
Name, strength and pharmaceutical form	POWDOX 125 mg/g premix for medicated feeding stuff for pigs.
Applicant	VETPHARMA ANIMAL HEALTH S.L. Les Corts, 23 -08028 Barcelona (Spain)
Active substance(s)	Doxycycline (hyclate)
ATC Vet code	QJ01AA02
Target species	Pigs (pigs for fattening)
Indication for use	Treatment and prevention of pleuropneumonia caused by *Actinobacillus pleuropneumoniae* susceptible to doxycycline. The presence of the disease in the herd should be established before use.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MINISTERIO DE SANIDAD,
SERVICIOS SOCIALES
E IGUALDAD
Agencia Española de Medicamentos y Productos Sanitarios

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	24/02/2015
Date product first authorised in the Reference Member State (MRP only)	-
Concerned Member States for original procedure	BE, CY, EL, HU, PL, PT.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

MINISTERIO DE SANIDAD,
SERVICIOS SOCIALES
E IGUALDAD
Agencia Española de Medicamentos y Productos Sanitarios

II. QUALITY ASPECTS

A. Composition

The product contains Doxycycline (as doxycycline hyclate) and excipients Propylene glycol and Flour of hazelnut and almond shell.

The container/closure system consist of a 25 kg kraft paper bags of three ply with an inner layer of Low Density Polyethylene. The particulars of the containers and controls performed are provided and conform to the regulation.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is doxycycline hyclate, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The CEP is included according to the European Pharmacopoeia.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products> (pharmaceuticals)

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

The retest period of the active substance is declared by the CEP.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

In-use stability after first opening the immediate packaging has been demonstrated for 2 months according to the relevant European guideline.

The claim of a 1 month stability after incorporation into meal or pelleted feed is based on the demonstration of stability for a batch broached and stored one month at 25°C/60% RH.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Not applicable.

MINISTERIO DE SANIDAD,
SERVICIOS SOCIALES
E IGUALDAD
Agencia Española de Medicamentos y Productos Sanitarios

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL) (*for pharmaceuticals only)*

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of safety tests are not required.

The safety aspects of this product is/are identical to the reference product

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users, the environment, and to consumers.

III.A Safety Testing

Pharmacological Studies

Since the application has been submitted in accordance with Article 13 (1) (Directive 2001/82/EC, as amended by Directive 2004/28/EC), results of pharmacological tests are not required.

The pharmacological details of this product are the same as those of the reference product.

Toxicological Studies

Since the application has been submitted according to Article 13(1), (Directive 2001/82/EC, as amended by Directive 2004/28/EC) relating to the authorization of generic medicinal products, results of toxicological tests are not required.

The toxicological aspects of this product are the same as those of the reference product.

User Safety

The applicant has provided a user risk assessment in compliance with the relevant guideline which shows that the use of the veterinary medicinal product does not entail any risk for the person administering it when warnings and precautions as listed on the product literature are properly followed.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that further assessment was required. In Phase II, the comparison of the terrestrial PNECs with the PEC_{soil} and the corresponding $PEC_{surface\ water}$ and $PEC_{groundwater}$ indicated that the use of the medicinal product in the target specie as recommended in the SPC will not pose a risk to the environment.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Residue Studies

Due to the type of application and in accordance with Article 13(1) (Directive 2001/82/EC, as amended by Directive 2004/28/EC), no studies of depletion of residues are required.

MRLs

Doxycycline is included in Table I of Regulation 37/2010, through Regulation 470/2009 establishing the MRLs for the target species as follows:

MRLs are listed below:

Pharmacologically active substance	Marker residue	Animal species	Target tissues	MRLs
Doxycycline	Doxycycline	Porcine	Muscle	100 µg/kg
			Skin and fat	300 µg/kg
			Liver	300 µg/kg
			Kidney	600 µg/kg

Withdrawal Periods

Since both products are considered equivalent in terms of active substance and excipients it can be stated that, their residue profile will be similar and therefore, the **withdrawal period** of the reference product can be applied to *POWDOX 125 mg/g:*

Pigs for fattening:
Meat and offal: 5 days

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

Pharmacology

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, pharmacology studies are not required.

Tolerance in the Target Species of Animals

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, tolerance studies are not required.

Resistance

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, data regarding development of resistance are not required.

Adequate warnings and precautions appear on the product literature.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, clinical trials are not required.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>

or

Complete this section for extensions to the same VPA range or defined, significant variations, using the table shown below.

Some examples of significant changes in safety or efficacy data are:

- *Changes to pharmacokinetic data leading to a change in the SPC*
- *Changes to toxicological data leading to a change in the SPC*
- *Changes to user safety warnings*
- *Changes to ecotoxicological information as given in the SPC or changes to disposal warnings*
- *New residue studies in new target species or tissues*
- *Reassessment of residue data or new studies resulting from changes to MRL*
- *Changes to withdrawal period*
- *Changes to target species*
- *Changes to target species tolerance data leading to change in warnings/precautions for target species*
- *New or changed indications*

Significant changes in administrative or quality data include any Type II change, which affects the initial report. The following Type IA or IB changes may also apply:

- *Name of product [Type IA: 2]*
- *Name of active substance [Type IA: 3}*
- *MAH [Type IA: 1]*
- *Composition of the medicinal product [Type IB: 18, Type IA/B: 25, 34, 35, 39]*
- *Container/closure system [Type 1/B: 26, 28, 29, 36, 41, 43]*
- *Method of preparation [Type 1B: 33]*
- *Active substance specification [Type IB: 25]*
- *CEP [Type IA/B: 15]*
- *Re-test period or storage conditions of active substance [Type IB: 17]*
- *Excipient specifications [Type 1A/B: 25]*
- *Packaging materials[Type 1A/B: 28, 29, 36, 41, 43]*
- *TSE [Type 1A: 16, 22]*
- *Shelf-life or storage conditions of the finished product [Type 1B: 42]*

Quality changes

Summary of change (Application number)	**Section updated in Module 3**	**Approval date**
<Example: Change to active substance specification> (MS/V/XXX/X/IB/XX)	N/A	

Safety/efficacy changes

Summary of change (Type; application number)	**Section updated in Module 3**	**Approval date**
<Example: Addition of target species - pigs> (MS/V/XXX/X/II/XX)	<IIIA> <IIIB> <IV>	

MINISTERIO DE SANIDAD,
SERVICIOS SOCIALES
E IGUALDAD
Agencia Española de Medicamentos y Productos Sanitarios